PARIS, February 17,2016 /PRNewswire/ --
Level 1 American Depositary Receipts (ADR) trades under the symbol MKEAY
Mauna Kea Technologies (Euronext: MKEA, FR0010609263; OTCQX: MKEAY), inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy (CLE) platform, today announced that the Company has commenced trading of its sponsored Level 1 American Depositary Receipts (ADRs) in the United States on OTCQX® International, a tier of the OTCQX Best Market ("OTCQX"). Trading of Mauna Kea Technologies ADRs on OTCQX has commenced under the symbol MKEAY. Each ADR represents 2 ordinary shares on Euronext.
Mauna Kea Technologies will continue to trade on EURONEXT under its existing code MKEA. OTCQX International is a tier of the OTCQX market reserved for high-quality non-U.S. companies listed on a qualified foreign stock exchange. U.S. investors can find current financial disclosures and Real-Time Level 2 quotes for Mauna Kea Technologies here.
"Continuing to build on a strong presence in North America is strategically important to Mauna Kea Technologies. With 10 separate FDA clearances, 140 U.S. Cellvizio installations today including the majority of leadings U.S. academic medical centers and a global commercial partnership in urology with a leading American medical device firm, Cook Medical, we have solid foundations in the American market. Later this year, will we relocate our U.S. operations to Boston, a recognized nexus for medical innovation. Finally, in joining the OTCQX market, we are pleased to achieve a milestone that places the Company in close proximity to many of the world's most sophisticated healthcare investors." said Sacha Loiseau, CEO and Founder of Mauna Kea Technologies.
"We are pleased Mauna Kea Technologies has chosen to trade on OTCQX," said Jason Paltrowitz, Executive Vice President of Corporate Services at OTC Markets Group. "The OTCQX market offers investor-focused companies an efficient and effective way to enhance their visibility with U.S. investors through high-quality disclosure, transparent trading and ease of access to company information."
BNY Mellon will serve as Mauna Kea Technologies' Principal American Liaison ("PAL") on OTCQX, responsible for providing professional guidance on OTCQX requirements. Click here for more information on the Mauna Kea Technologies' ADR in the US.
About Mauna Kea Technologies
Mauna Kea Technologies is a global medical device company focused on eliminating uncertainties related to the diagnosis and treatment of cancer thanks to real time in vivo microscopic visualization. The Company's flagship product, Cellvizio, has received clearance to sell a wide range of applications in more than 40 countries, including the United States, Europe, Japan, China, Canada, Brazil and Mexico.
For more information on Mauna Kea Technologies, visit www.maunakeatech.com
Mauna Kea Technologies
Investors relations US
Sebastien Cadet
Global Marketing Director and OEM Leader
investors@maunakeatech.com
France and Europe
NewCap - Investor Relations | Strategic Communication
Florent Alba/Pierre Laurent
Tel: +33 (0)1 44 71 94 94
maunakea@newcap.fr
This is a disclosure announcement from PR Newswire.